The monoclonal antibody in development as maintenance therapy for people with moderately to severely active ulcerative colitis was more effective than placebo.
/PRNewswire/ Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001).
A long-term maintenance study suggested continuing mirikizumab for 104 weeks is safe and provides durable benefit in patients with active ulcerative colitis.
Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.